Clario and Tufts Center for the Study of Drug Development (CSDD) to present new results at the DIA 2023 Annual Global Meeting showing a sustained under-representation of minority communities in pivotal trials supporting new drug and biologic approvals. Data from 1,165 pivotal trials for 550 NDAs and BLAs were collected (FDA approvals 2007 – 2021) … Read more
Clario and Tufts Center for the Study of Drug Development (CSDD) to present new results at the DIA 2023 Annual Global Meeting showing a sustained under-representation of minority communities in pivotal trials supporting new drug and biologic approvals. Data from 1,165 pivotal trials for 550 NDAs and BLAs were collected (FDA approvals 2007 – 2021) … Read more
Clario joins partnership supporting White House Cancer Moonshot Clario brings over 50 years of experience in oncology clinical trials to the partnership and has been involved in over 75% of all FDA approvals of oncology medicines since 2012 Clario scientists have supported nearly 5,000 studies in oncology in over 160,000 sites worldwide involving more than … Read more
Clario joins partnership supporting White House Cancer Moonshot Clario brings over 50 years of experience in oncology clinical trials to the partnership and has been involved in over 75% of all FDA approvals of oncology medicines since 2012 Clario scientists have supported nearly 5,000 studies in oncology in over 160,000 sites worldwide involving more than … Read more